このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation (POWER-LT)

2026年4月24日 更新者：Kalliopi Anna Poulia

Evaluation of Protein Distribution Optimization With Exercise Regimen on Nutritional Status, Body Composition and Functional Status in Patients Awaiting Liver Transplantation: The POWER-LT Randomized Clinical Trial

This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C) on nutritional status, body composition and functional status in patients awaiting liver transplantation.

調査の概要

状態

募集

条件

介入・治療

詳細な説明

Malnutrition and sarcopenia affect many patients awaiting liver transplantation and is associated with reduced quality of life and increased mortality. According to the current European Society for Clinical Nutrition and Metabolism (ESPEN) and European Association for the Study of the Liver (EASL) guidelines, a target of 1.2-1.5 g protein per kg body weight daily is recommended for patients with decompensated liver cirrhosis. While evidence supports that even protein distribution enhances muscle protein synthesis in healthy adults, specific protein timing recommendations are lacking for patients with end-stage liver disease.

Therefore, this randomized controlled trial aims to investigate the effects of a 12-week diet with even protein distribution plus exercise (Group A) versus skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice (Group C), primarily on nutritional status, body composition and functional status, and secondarily on anthropometric measurements, laboratory parameters, quality of life, disease severity, complications and mortality in liver transplant candidates. Moreover, late postoperative parameters, including length of hospital stay, length of intensive care unit stay, duration of mechanical ventilation, postoperative complications, hospital readmissions, reoperations and mortality will be examined for those who undergo transplantation.

研究の種類

介入

入学 (推定)

90

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前：Kalliopi Anna Poulia
  • 電話番号：+30 2105294668
  • メール：lpoulia@aua.gr

研究連絡先のバックアップ

  • 名前：Evangelos Cholongitas
  • 電話番号：+30 2132061643
  • メール：echolog@med.uoa.gr

研究場所

  • ギリシャ
    • Attica
      • Athens、Attica、ギリシャ、11855
        • 募集
        • Agricultural University of Athens
        • コンタクト：
          • Kalliopi Anna Poulia
          • 電話番号：+30 2105294668
          • メール：lpoulia@aua.gr
      • Athens、Attica、ギリシャ、11527
        • 募集
        • Laiko General Hospital of Athens
        • コンタクト：

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • End-stage liver disease, diagnosed by transient elastography (FibroScan) or imaging-based evaluation with compatible clinical picture
  • Referred for liver transplantation and evaluated to have a high likelihood of being listed, according to primary hepatologist assessment, or already listed for liver transplantation
  • No prior formal dietary advice

Exclusion Criteria:

  • Age < 18 years old
  • Estimated waiting time for liver transplantation < 3 months
  • Estimated life expectancy < 3 months
  • Chronic kidney disease requiring protein restriction
  • Exercise contraindicated (e.g., active or recent variceal bleeding, severe grade of hepatic encephalopathy, refractory ascites, etc.)
  • Unstable or severe psychiatric disorder
  • Pregnancy or lactation
  • Inability to provide written informed consent

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：支持療法
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：なし（オープンラベル）

武器と介入

参加者グループ / アーム
介入・治療
実験的：Diet with even protein distribution plus exercise program
行動：Diet with even protein distribution plus exercise program
Diet of 1.2-1.5 g protein/kg dry body weight/day, equally divided (33.3% at 3 main meals) | Exercise program: 3 days/week aerobic and 2 days/week resistance | Duration: 12 weeks
実験的：Diet with skewed protein distribution plus exercise program
行動：Diet with skewed protein distribution plus exercise program
Diet of 1.2-1.5 g protein/kg dry body weight/day, unequally divided (10.0% at breakfast, 60.0% at lunch, 30.0% at dinner) | Exercise program: 3 days/week aerobic and 2 days/week resistance | Duration: 12 weeks
アクティブコンパレータ：Standard dietary and physical activity advice
行動：Standard dietary and physical activity advice
Standard dietary and physical activity advice | Duration: 12 weeks

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Changes in Global Leadership Initiative on Malnutrition (GLIM)-defined malnutrition
時間枠：Baseline, 12 weeks
Malnutrition will be diagnosed using the Global Leadership Initiative on Malnutrition (GLIM) criteria. Diagnosis requires at least 1 phenotypic criterion and 1 etiologic criterion. Phenotypic criteria include: a. Non-votional weight loss (%): > 5% within past 6 months or > 10% beyond 6 months, b. Low body mass index (BMI, kg/m^2): < 20 kg/m^2 if < 70 years or < 22 kg/m^2 if > 70 years, c. Reduced muscle mass, assessed by validated body composition measuring techniques [e.g. Dual-Energy X-ray Absorptiometry (DEXA), Bioelectrical Impedance Analysis (BIA) or Computed Tomography (CT)]. Etiologic criteria include: a. Reduced food intake or assimillation: ≤ 50% of energy requirements > 1 week or any reduction for > 2 weeks or any chronic gastrointestinal condition that adversely impacts food assimilation or absorption, b. Inflammation: acute disease/injury or chronic disease-related.
Baseline, 12 weeks
Changes in Computed Tomography (CT)-derived muscle mass
時間枠：Baseline, 12 weeks
Muscle mass will be assessed using the Skeletal Muscle Index (SMI, cm^2/m^2). SMI will be calculated by measuring the total cross-sectional area of skeletal muscles, from a single cross-sectional Computed Tomography (CT) image at L3 vertebral level, using Hounsfield Units of -29 to +150 HU, and normalizing to height squared (m^2).Thresholds for reduced SMI will be considered < 50 cm^2/m^2 for men and < 39 cm^2/m^2 for women.
Baseline, 12 weeks
Changes in handgrip strength (kg)
時間枠：Baseline, 12 weeks
Handgrip strength (kg) will be assessed using a digital handgrip dynamometer. Thresholds for reduced muscle strength will be considered < 27 kg for men and < 16 kg for women.
Baseline, 12 weeks
Changes in Short Physical Performance Battery (SPPB) score
時間枠：Baseline, 12 weeks
The Short Physical Performance Battery (SPPB) includes 3 components: 3-positions balance testing (sec) (0-4 points), 4-meter gait speed test (sec) (0-4 points) and 5-times chair stand test (sec) (0-4 points), with a total score of 0-12. Higher scores indicate a better physical performance: 0-3 points for worst physical performance, 4-9 points for reduced physical performance and 10-12 points for best physical performance.
Baseline, 12 weeks
Changes in Liver Frailty Index
時間枠：Baseline, 12 weeks
The Liver Frailty Index includes 3 components: handgrip strength (kg), 5-times chair stand test (sec) and 3-positions balance testing (sec). Higher scores indicate a greater degree of frailty.
Baseline, 12 weeks
Changes in European Working Group on Sarcopenia in Older People 2 (EWGSOP2)-derived sarcopenia
時間枠：Baseline, 12 weeks
Sarcopenia will be diagnosed using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) criteria. Diagnosis requires low muscle strength and low muscle mass. Reduced muscle strength will be diagnozed by: a. Low handgrip strength (kg): > 27 kg for men and > 16 kg for women or b. Low chair stand test (sec): >15 sec for 5-times chair stand test. Reduced muscle mass will be diagnozed by: a. Low Appendicular Skeletal Muscle Mass (ASM, kg): < 20 kg for men and < 15 kg for women or b. Low Appendicular Skeletal Muscle Mass Index (ASMI, kg/m^2): <7.0 kg/m^2 for men and < 5.5 kg/m^2 for women.
Baseline, 12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Nutritional Risk Screening-2002 (NRS-2002)-derived nutritional risk
時間枠：Baseline
Nutritional risk will be assessed using the Nutritional Risk Screening-2002 (NRS-2002) tool. Higher scores indicate greater nutritional risk: < 3 points indicate good nutritional status and ≥ 3 nutritional risk.
Baseline
Malnutrition Screening Tool (MST)-derived nutritional risk
時間枠：Baseline
Nutritional risk will be assessed using the Malnutrition Screening Tool (MST) tool. Higher scores indicate greater nutritional risk: < 2 points indicate good nutritional status and ≥ 2 nutritional risk.
Baseline
Malnutrition Universal Screening Tool (MUST)-derived nutritional risk
時間枠：Baseline
Nutritional risk will be assessed using the Malnutrition Universal Screening Tool (MUST) tool. Higher scores indicate greater nutritional risk: 0 points indicate low risk, 1 point medium risk and ≥ 2 high risk.
Baseline
Short Nutritional Assessment Questionnaire (SNAQ)-derived nutritional risk
時間枠：Baseline
Nutritional risk will be assessed using the Short Nutritional Assessment Questionnaire (SNAQ) tool. Higher scores indicate greater nutritional risk: 0-1 points indicate low risk, 2 points medium risk and ≥ 3 points high risk.
Baseline
Mini Nutritional Assessment-Short Form (MNA-SF)-derived nutritional status
時間枠：Baseline
Nutritional risk will be assessed using the Mini Nutritional Assessment-Short Form (MNA-SF) tool. Lower scores indicate greater nutritional risk: 12-14 points indicate good nutritional status, 8-11 points risk of malnutrition and 0-7 points malnutrition.
Baseline
Nutritional Risk Index (NRI)-derived nutritional risk
時間枠：Baseline
Nutritional risk will be assessed using the Nutritional Risk Index (NRI) tool. Lower scores indicate greater nutritional risk: > 100.0 indicate good nutritional status, 97.5-100.0 low risk, 83.5-97.5 medium risk and < 83.5 high risk.
Baseline
Prognostic Nutritional Index (PNI)-derived nutritional status
時間枠：Baseline
Nutritional risk will be assessed using the Prognostic Nutritional Index (PNI) tool. Lower scores indicate greater nutritional risk: ≥ 50 indicate good nutritional status, < 50 low risk, < 45 medium risk and < 40 high risk.
Baseline
Controlling Nutritional Status (CONUT)-derived nutritional status
時間枠：Baseline
Nutritional risk will be assessed using the Controlling Nutritional Status (CONUT) tool. Higher scores indicate greater nutritional risk: 0-1 points indicate good nutritional status, 2-4 points low risk, 5-8 medium risk and 9-12 high risk.
Baseline
Liver Disease Undernutrition Screening Tool (LDUST)-derived nutritional risk
時間枠：Baseline
Nutritional risk will be assessed using the Liver Disease Undernutrition Screening Tool (LDUST) tool. ≥ 5 answers "A" indicate good nutritional status and ≥ 2 answers "B" and/or "C" malnutrition.
Baseline
Royal Free Hospital-Nutritional Prioritizing Tool (RHT-NPT)-derived nutritional status
時間枠：Baseline
Nutritional risk will be assessed using the Royal Free Hospital-Nutritional Prioritizing Tool (RHT-NPT) tool. Higher scores indicate greater nutritional risk: 0 points indicate low risk, 1 point medium risk and 2-7 points high risk.
Baseline
Dual-Energy X-ray Absorptiometry (DEXA)-derived muscle mass
時間枠：Baseline
Muscle mass will be assessed using the Appendicular Skeletal Muscle Mass Index (ASMI, kg/m^2) using Dual-Energy X-ray Absorptiometry (DEXA). Thresholds for reduced muscle mass will be considered < 7.0 for men and < 5.4 for women.
Baseline
Food Frequency Questionnaire (FFQ)-derived dietary habits
時間枠：Baseline
Long-term dietary habits will be assessed using a semi-quantitative Food Frequency Questionnaire (FFQ).
Baseline
International Physical Activity Questionnaire (IPAQ)-derived physical activity levels
時間枠：Baseline
Physical activity levels will be assessed using the International Physical Activity Questionnaire (IPAQ)-Short Form. IPAQ includes 7 open-ended questions. Higher scores (MET-min/week) indicate higher physical activity levels.
Baseline
Changes in Bioelectrical Impedance Analysis (BIA)-derived muscle mass
時間枠：Baseline, 12 weeks
Muscle mass will be assessed using the Appendicular Skeletal Muscle Mass Index (ASMI, kg/m^2) by Bioelectrical Impedance Analysis (BIA). Thresholds for reduced ASMI will be considered < 7.0 for men and < 5.7 for women.
Baseline, 12 weeks
Changes in body weight (kg)
時間枠：Baseline, 12 weeks
Body weight (kg) will be measured using a calibrated weight scale.
Baseline, 12 weeks
Changes in Body Mass Index (BMI, kg/m^2)
時間枠：Baseline, 12 weeks
Body Mass Index (BMI, kg, m^2) will be calculated by dividing body weight (kg) by height squared (m^2), which will be measured using a calibrated stadiometer.
Baseline, 12 weeks
Changes in Mid-Arm Muscle Circumference (MAMC, cm)
時間枠：Baseline, 12 weeks
Mid-Arm Muscle Circumference (MAMC, cm) will be calculated using the following formula: MAMC (cm) = Mid-Arm Circumference (MAC, cm) - [0.314*Triceps Skinfold Thickness (TSF, mm)]. MAC will be measured using a non-stretchable measuring tape and TSF using a calibrated skinfold caliper. Thresholds for reduced MAMC will be considered < 25 cm for men and < 22 cm for women.
Baseline, 12 weeks
Changes in Bristol Stool Chart
時間枠：Baseline, 12 weeks
Bowel habits will be assessed using the Bristol Stool Chart. Bristol Stool Chart classifies stool forms in 7 types: types 1-2 indicate constipation, types 3-4 normal stool form, and types 5-7 looser stools tending toward diarrhea
Baseline, 12 weeks
Changes in Chronic Liver Disease Questionnaire (CLDQ)
時間枠：Baseline, 12 weeks
Quality of life will be assessed using the Chronic Liver Disease Questionnaire (CLDQ). CLDQ includes 29 items in 6 domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Each is scored on a 7-point scale, with higher domain and total scores indicating a better quality of life.
Baseline, 12 weeks
Changes in aspartate aminotransferase (AST, U/L)
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in alanine aminotransferase (ALT, U/L)
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review
Baseline, 12 weeks
Changes in alkaline phosphatase (ALP, U/L)
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in gamma-glutamyltransferase (GGT, U/L)
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in total bilirubin (mg/dL)
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in direct bilirubin (mg/dL)
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in International Normalized Ratio (INR)
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in MELD-Na score
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review. Higher MELD-Na scores indicate greater severity of chronic liver disease and higher predictive risk of mortality (< 17 points: <2%, 17-20 points: 3-4%, 21-22 points: 7-10%, 23-26 points: 14-15%, 27-31 points: 27-32%, ≥ 32 points: 65-66%)
Baseline, 12 weeks
Changes in Child-Pugh score
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review. Higher Child-Pugh scores indicate greater severity of liver cirrhosis [class A (5-6 points): mild, class B: (7-9 points): moderate, class C (10-15) points: severe]
Baseline, 12 weeks
Changes in presence of oedema and/or ascites
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in presence of jaundice
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in presence of variceal bleeding
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in presence of infections
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Changes in presence of hepatic encephalopathy
時間枠：Baseline, 12 weeks
Data will be collected through medical chart review.
Baseline, 12 weeks
Mortality
時間枠：From baseline to 12 weeks
Data will be collected through medical chart review.
From baseline to 12 weeks

その他の成果指標

結果測定
メジャーの説明
時間枠
Adherence to the program
時間枠：4 weeks, 8 weeks, 12 weeks
Adherence to the program will be assessed using 24-hour recalls and physical activity diaries.
4 weeks, 8 weeks, 12 weeks
Satisfaction with the program
時間枠：12 weeks
Satisfaction with the program will be assessed using a Likert scale: very satisfied, fairly satisfied, neither satisfied nor dissatisfied, slightly dissatisfied and not at all satisfied
12 weeks
Global Leadership Initiative on Malnutrition (GLIM)-defined malnutrition
時間枠：3 months post-transplantation
Malnutrition will be diagnosed using the Global Leadership Initiative on Malnutrition (GLIM) criteria. Diagnosis requires at least 1 phenotypic criterion and 1 etiologic criterion. Phenotypic criteria: a. Non-votional weight loss (%): > 5% within past 6 months or >10% beyond 6 months b. Low body mass index (BMI, kg/m^2): < 20 kg/m^2 if < 70 years or < 22 kg/m^2 if > 70 years c. Reduced muscle mass, assesses by validated body composition measuring techniques [e.g. Dual-Energy X-ray Absorptiometry (DEXA), Bioelectrical Impedance Analysis (BIA) or Computed Tomography (CT) Etiologic criteria: a. Reduced food intake or assimillation: ≤ 50% of energy requirements > 1 week or any reduction for > 2 weeks or any chronic gastrointestinal condition that adversely impacts food assimilation or absorption b. Inflammation: acute disease/injury or chronic disease-related
3 months post-transplantation
Computed Tomography (CT)-derived muscle mass
時間枠：3 months post-transplantation
Muscle mass will be assessed using the Skeletal Muscle Index (SMI, cm^2/m^2). SMI will be calculated by measuring the total cross-sectional area of skeletal muscles, from a single cross-sectional Computed Tomography (CT) image at L3 vertebral level, using Hounsfield Units of -29 to +150 HU, and normalizing to height squared (m^2).Thresholds for reduced SMI will be considered < 50 cm^2/m^2 for men and < 39 cm^2/m^2 for women.
3 months post-transplantation
Handgrip strength (kg)
時間枠：3 months post-transplantation
Handgrip strength (kg) will be assessed using a digital handgrip dynamometer. Thresholds for reduced muscle strength will be considered < 27 kg for men and < 16 kg for women.
3 months post-transplantation
Short Physical Performance Battery (SPPB) score
時間枠：3 months post-transplantation
The Short Physical Performance Battery (SPPB) includes 3 components: 3-positions balance testing (sec) (0-4 points), 4-meter gait speed test (sec) (0-4 points) and 5-times chair stand test (sec) (0-4 points), with a total score of 0-12. Higher scores indicate a better physical performance: 0-3 points for worst physical performance, 4-9 points for reduced physical performance and 10-12 points for best physical performance.
3 months post-transplantation
Liver Frailty Index
時間枠：3 months post-transplantation
The Liver Frailty Index includes 3 components: handgrip strength (kg), 5-times chair stand test (sec) and 3-positions balance testing (sec). Higher scores indicate a greater degree of frailty.
3 months post-transplantation
European Working Group on Sarcopenia in Older People 2 (EWGSOP2)-derived sarcopenia
時間枠：3 months post-transplantation
Sarcopenia will be diagnosed using the European Working Group on Sarcopenia in Older People 2 (EWGSOP2) diagnostic criteria. Diagnosis requires the presence of low muscle strength and low muscle mass. Reduced muscle strength: a. Low handgrip strength (kg): > 27 kg for men and > 16 kg for women b. Low chair stand test (sec): >15 sec for 5 rises Reduced muscle mass: a. Low Appendicular Skeletal Muscle Mass (ASM, kg): < 20 kg for men and < 15 kg for women b. Low Appendicular Skeletal Muscle Mass Index (ASMI, kg/m^2): <7.0 kg/m^2 for men and < 5.5 kg/m^2 for women
3 months post-transplantation
Body weight (kg)
時間枠：3 months post-transplantation
Body weight (kg) will be measured using a calibrated weight scale.
3 months post-transplantation
Body Mass Index (BMI, kg, m^2)
時間枠：3 months post-transplantation
Body Mass Index (BMI, kg, m^2) will be calculated by dividing body weight (kg) by height squared (m^2), which will be measured using a calibrated stadiometer.
3 months post-transplantation
Mid-Arm Muscle Circumference (MAMC, cm)
時間枠：3 months post-transplantation
Mid-Arm Muscle Circumference (MAMC, cm) will be calculated using the following formula: MAMC (cm) = Mid-Arm Circumference (MAC, cm) - [0.314*Triceps Skinfold Thickness (TSF, mm)]. MAC will be measured using a non-stretchable measuring tape and TSF using a calibrated skinfold caliper. Thresholds for reduced MAMC will be considered < 25 cm for men and < 22 cm for women.
3 months post-transplantation
Bristol Stool Chart
時間枠：3 months post-transplantation
Bowel habits will be assessed using the Bristol Stool Chart. Bristol Stool Chart classifies stool forms in 7 types: types 1-2 indicate constipation, types 3-4 normal stool form, and types 5-7 looser stools tending toward diarrhea
3 months post-transplantation
Chronic Liver Disease Questionnaire (CLDQ)
時間枠：3 months post-transplantation
Quality of life will be assessed using the Chronic Liver Disease Questionnaire (CLDQ). CLDQ includes 29 items in 6 domains: fatigue, activity, emotional function, abdominal symptoms, systemic symptoms, and worry. Each is scored on a 7-point scale, with higher domain and total scores indicating a better quality of life.
3 months post-transplantation
Aspartate aminotransferase (AST, U/L)
時間枠：3 months post-transplantation
Data will be collected through medical chart review.
3 months post-transplantation
Alanine aminotransferase (ALT, U/L)
時間枠：3 months post-transplantation
Data will be collected through medical chart review.
3 months post-transplantation
Alkaline phosphatase (ALP, U/L)
時間枠：3 months post-transplantation
Data will be collected through medical chart review.
3 months post-transplantation
Gamma-glutamyltransferase (GGT, U/L)
時間枠：3 months post-transplantation
Data will be collected through medical chart review.
3 months post-transplantation
Total bilirubin (mg/dL)
時間枠：3 months post-transplantation
Data will be collected through medical chart review.
3 months post-transplantation
Direct bilirubin (mg/dL)
時間枠：3 months post-transplantation
Data will be collected through medical chart review.
3 months post-transplantation
International Normalized Ratio (INR)
時間枠：3 months post-transplantation
Data will be collected through medical chart review.
3 months post-transplantation
Length of hospital stay
時間枠：From transplantation to 3 months post-transplantation
Data will be collected through medical chart review.
From transplantation to 3 months post-transplantation
Length of intensive care unit stay
時間枠：From transplantation to 3 months post-transplantation
Data will be collected through medical chart review.
From transplantation to 3 months post-transplantation
Duration of mechanical ventilation
時間枠：From transplantation to 3 months post-transplantation
Data will be collected through medical chart review.
From transplantation to 3 months post-transplantation
Postoperative complications
時間枠：From transplantation to 3 months post-transplantation
Data will be collected through medical chart review.
From transplantation to 3 months post-transplantation
Hospital readmissions
時間枠：From transplantation to 3 months post-transplantation
Data will be collected through medical chart review.
From transplantation to 3 months post-transplantation
Reoperations
時間枠：From transplantation to 3 months post-transplantation
Data will be collected through medical chart review.
From transplantation to 3 months post-transplantation
Mortality
時間枠：From transplantation to 3 months post-transplantation
Data will be collected through medical chart review.
From transplantation to 3 months post-transplantation

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Kalliopi Anna Poulia

協力者

Laikο General Hospital, Athens

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月8日

一次修了 (推定)

2028年7月1日

研究の完了 (推定)

2029年7月1日

試験登録日

最初に提出

2026年3月26日

QC基準を満たした最初の提出物

2026年4月24日

最初の投稿 (実際)

2026年5月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年5月1日

QC基準を満たした最後の更新が送信されました

2026年4月24日

最終確認日

2026年3月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 113/05.12.2025

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する